͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
| | | | We’re proud to launch a £10m Cancer Data Driven Detection initiative to transform how we use data to assess cancer risk, advance early detection and improve precision prevention.
Over the next five years, this initiative will pull together and increase access to data from diverse sources, including health records, genomics, demographics, family history and behavioural, to create models that allow researchers to accurately predict people most likely to get cancer.
Going one step further, the programme will develop powerful new data-driven tools to calculate an individual’s risk of cancer.
The initiative will deliver on several recommendations from our roadmap for early detection and diagnosis and aligns with our prevention and research data strategies.
Directed by Antonis Antoniou, the Cancer Data Driven Detection initiative is jointly supported by Cancer Research UK, the National Institute for Health & Care Research, the Engineering & Physical Sciences Research Council, Health Data Research UK and Administrative Data Research UK.
|
| | |
| | |
|
|
|
|
Funding & Research Opportunities |
| Get in touch with our office for confidential advice on eligibility, remit and funding options prior to applying. |
|
| | | | | | | | | | | | | | | | | | | | Applications accepted year round |
|
|---|
| | | | | | Applications accepted all year round |
|
|---|
| | | | | | Applications accepted all year round |
|
|---|
|
| | |
|
|
Showcase your work at our prevention conference |
| Want to showcase your prevention research to an international audience?
Our Cancer Prevention Research Conference, taking place in London from 25–27 June in partnership with the American Cancer Society and the National Cancer Institute, could be the perfect occasion for you.
Submit your abstract under one of the following session themes for the opportunity to present a poster and speak alongside our expert line-up: |
| | The convergence of ageing, genetics and cancer risk Pre-cancer biology and interception opportunities Integrated view of inequalities in cancer risk and incidence Implementation of precision prevention interventions using repurposed drugs | | |
|
|
|
|
|
Don’t miss out: nominations for the Innovation and Entrepreneurship Awards 2025 are open |
| Our innovation arm, Cancer Research Horizons, hosts this annual celebration of translational researchers who are transforming discoveries into meaningful benefits for patients. This is a great opportunity to raise the profile of these important contributions. Is this you, or someone who inspires you?
Winners can expect:
● £5,000-£15,000 to boost their research
● A network of like-minded entrepreneurs
● A community of industry connections
● A chance to showcase their work at the Awards ceremony on 10 July
The deadline to submit your nomination is
17 March 2025.
|
| | |
|
|
|
International collaboration to bring rare cancer treatment into the clinic |
| Our Centre for Drug Development is collaborating with the Norwegian biotech Cytovation to launch a Phase 2 trial of the new synthetic peptide CY-101 in adrenocortical carcinoma (ACC). CY-101 selectively destroys cancer cells while simultaneously inhibiting the Wnt/β-catenin signalling pathway, a key driver of immunotherapy resistance in cancers such as ACC.
Trials in this indication are long awaited as ACC is a rare and aggressive cancer with limited treatment options.
This trial has been made possible thanks to a strategic partnership with the Norwegian Cancer Society, which is contributing funding and access to additional patients and sites. Multiple sites across the UK and Europe will be used to ensure robust patient recruitment. |
| | |
|
|
|
National disability staff survey: your voice |
| Those working in higher education and who self-identify as being disabled, neurodivergent and/or living with a long-term health condition and/or chronic illness are being invited to take part in a National Disability Staff Survey. This survey will help ensure that disabled staff in higher education are seen, valued and supported to thrive.
The data collected from this survey will support the development of RIDE HIGHER (Realising the Inclusion of Disabled Employees in Higher Education), a new framework to share best practice across the sector and drive our journey towards greater equity for disabled colleagues.
|
| | |
|
|
|
| | | | | | | Are you interested in hearing from researchers working at the interface between discovery and clinical research?
Gudrun Schleiermacher (Institut Curie) is joining us for a webinar on how to maximise learnings from clinical research. Gudrun’s work focuses on the molecular mechanisms involved in cancer progression and clonal evolution in neuroblastoma and other aggressive paediatric cancers, with the aim to develop new therapeutic strategies.
Stay tuned for more speaker announcements and updates on social media with #ExploringCYPCancers.
Join the webinar on
12 February, 3–4:30pm (GMT).
| | |
| | | | | | | How suitable are "surrogate endpoints" as quicker, more accessible measures for evaluating new screening programmes?
Tune in to our webinar hosted in partnership with Consilium Scientific to find out more. Cancer and screening initiative experts Bethany Shinkins, Peter Sasieni, Hilary Robbins, and Sian Taylor-Phillips share their views on the use of surrogate endpoints for earlier cancer detection, discuss what the evidence suggests, and identify the steps and change-makers required to achieve consensus and drive progress in screening for cancer.
Join the webinar on
30 January at 5pm (GMT). | | |
|
|---|
|
|
|
|
How can we reduce the environmental impact of clinical trials? |
| There has been a real push to combat the significant impact of clinical trials, and we have witnessed the development of novel tools, education initiatives and collaborative networks to make them more sustainable.
We spoke to four innovators driving real change in the clinical trials community to find out what they’re doing and how it’s making a difference.
Learn from their insights into their specific experiences, how they implemented their strategies and their inspiration to play a part in transforming the environmental impact of clinical trials. |
| | |
|
|
|
#ResearchisBeautiful: last chance to submit your entry |
| The countdown is on – 25 January is the deadline to be considered for our first #ResearchIsBeautiful feature of 2025.
This is your chance to share the unique qualities that make your work extraordinary. From captivating images of your research to snapshots of collaboration or the spaces where innovation thrives, we’d love to see what inspires you.
Every beautiful moment counts. T&Cs apply, email your entry today. |
| | |
|
|
|
| | Together we are
beating cancer |
| | |
|---|
|
|
|
| | | You are playing a crucial role in helping us beat cancer, so we'd like to continue to keep you updated on what we're up to. You can manage your preferences and unsubscribe here.
Your details are safe with us. Check out our Privacy Policy.
Our supporters are at the heart of everything we achieve at Cancer Research UK. Read our Fundraising Promise.
This email is from Cancer Research UK. Cancer Research UK is a registered charity in England and Wales (1089464), Scotland (SC041666), the Isle of Man (1103) and Jersey (247). A company limited by guarantee. Registered company in England and Wales (4325234) and the Isle of Man (5713F). Registered address: 2 Redman Place, London, E20 1JQ. |
|
|
|
